Do You Need a Doctor to Get Peptides? Yes, and Here Is Exactly Why

Section 503(b) of the Act, codified at 21 U.S.C. 353(b), covers any drug that is not safe for use except under the supervision of a licensed practitioner because of its "toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use," and any drug an approved application limits to professional supervision. Such a drug "shall be dispensed only (i) upon a written prescription of a practitioner licensed by law to administer such drug, or (ii) upon an oral prescription of such practitioner which is reduced promptly to writing and filed by the pharmacist, or (iii) by refilling any such written or oral prescription if such refilling is authorized by the prescriber."

The same subsection carries the penalty: "The act of dispensing a drug contrary to the provisions of this paragraph shall be deemed to be an act which results in the drug being misbranded while held for sale." Misbranding is a federal violation for the pharmacy, which is why no licensed pharmacy will ship an injectable peptide on the strength of a checkout form. The label must also carry, at minimum, the symbol "Rx only."

An injectable peptide meets the definition on its method of use alone: subcutaneous injection, sterile preparation, a dose measured in syringe units, and contraindication screening are exactly the "method of its use" and "collateral measures" the statute describes. That is why BPC-157, semaglutide, tesamorelin and everything else in the table above are prescription-only, whether or not the molecule has an FDA-approved counterpart.

Compounded medications sit under a second section, 503A, codified at 21 U.S.C. 353a. It exempts a compounded drug from the approval, manufacturing-practice and labeling requirements that apply to manufactured drugs, but only when "the drug product is compounded for an identified individual patient based on the receipt of a valid prescription order," or on a prescriber's notation that a compounded product is necessary for that patient.

Read together: section 353(b) says a prescription drug may be dispensed only against a prescription, and section 353a says a compounded drug may exist only for an identified patient with one. There is no version of a compounded peptide a pharmacy can lawfully prepare for nobody in particular and sell to whoever asks.

The FDA's guidance on the prescription requirement under section 503A, issued in December 2016, reads the condition the same way: compounding is for "an identified individual patient based on a valid prescription order." It allows a pharmacy to prepare a limited amount in advance, "in limited quantities based on the history of prescriptions for identified patients," with a 30-day supply as the boundary in the circumstances it describes. A pharmacy filling a preparation for its own patients may keep a short runway ready; it cannot compound a shelf of vials for the open market.

Section 503A also governs what the pharmacy may compound with. A bulk drug substance may be used if it complies with a United States Pharmacopeia or National Formulary monograph, if it is a component of an FDA-approved drug, or if it appears on a list the FDA develops by regulation, and it must come from an FDA-registered establishment with a valid certificate of analysis. The section also bars compounding "regularly or in inordinate amounts" a drug that is essentially a copy of a commercially available product, and caps out-of-state shipments at 5 percent of a pharmacy's prescription orders in a state that has not signed a memorandum of understanding with the FDA.

This is why the pharmacy's identity matters as much as the prescriber's. A research-chemical vendor satisfies none of those conditions; a licensed 503A pharmacy has to satisfy all of them, and the certificate of analysis for your lot is a document you can ask for. Pepti publishes lot results at /quality/lab-results.

Neither column is FDA approved, and that surprises people. Compounded medication is legal and is not approved, which is explained in are peptides FDA approved. The FDA's own wording: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." The difference between the columns is not approval. It is whether a licensed clinician, a licensed pharmacy and a certificate of analysis stand behind the vial, or nobody does.

Several of the most-requested peptides are described in the research as supporting angiogenesis or growth-factor signaling. Animal work reports BPC-157 activating the VEGFR2 receptor (Journal of Molecular Medicine, 2017); thymosin beta-4, the parent protein of TB-500, is described as promoting endothelial cell migration in cell models (FASEB Journal, 1997); and a 1973 paper in Nature New Biology reported GHK-Cu stimulating growth in neoplastic liver tissue. None of this is evidence that a peptide causes cancer. It is the reason a physician reading "history of melanoma" slows down, asks when and what, and may decline a repair peptide or a growth-hormone secretagogue for that person specifically.

Sermorelin, tesamorelin, CJC-1295 and ipamorelin act by raising the body's own growth hormone output, and growth hormone reduces insulin sensitivity. The tesamorelin trials in HIV-infected adults monitored glucose throughout for that reason (New England Journal of Medicine, 2007). A patient with prediabetes, or an HbA1c nobody has checked in years, is a patient the physician wants labs on before writing tesamorelin or sermorelin; do you need bloodwork before peptides covers which molecules warrant it. Semaglutide and tirzepatide carry their own screen: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, with pancreatitis history and pregnancy as the other hard stops. Pepti's published prescribing rules name all three for GLP-1 requests.

There is no safety data for any compounded peptide in pregnancy or breastfeeding, and none is coming. A physician who learns a patient is pregnant, breastfeeding, or planning a pregnancy declines; Pepti screens for it on every treatment.

The intake asks for every current medication because the interactions are concrete. A GLP-1 alongside insulin or a sulfonylurea raises hypoglycemia risk; alongside warfarin it changes how the anticoagulant is absorbed. PT-141 is described in its trials as producing a transient rise in blood pressure after dosing (Journal of Women's Health, 2022), which is why uncontrolled hypertension is a reason to decline it. GHK-Cu delivers copper, so high-dose zinc or Wilson's disease is handled differently.

And sometimes the most useful thing a physician does with a peptide request is refuse it and order an X-ray. Night pain in a joint, progressive weakness, numbness that follows a nerve, a knee that locks: these need a diagnosis, not BPC-157.

There is no single federal statute that licenses a physician to prescribe by video or questionnaire. Medical licensure is a state function, and each state's medical board sets its own rules for when a physician-patient relationship exists, what evaluation is required before a prescription, and whether it may happen remotely. The Center for Connected Health Policy, which tracks these rules, puts it plainly: "There are a number of nuances and differences across the states related to the use of technology and prescribing." This page does not list state-by-state rules, because they change and because the only one that matters to you is the one in the state you are standing in.

The one requirement that does not vary is licensure in the patient's state. The Federation of State Medical Boards' board-by-board survey records that all state medical boards, plus those of the District of Columbia, Puerto Rico and the Virgin Islands, "require that physicians engaging in telemedicine are licensed in the state in which the patient is located," or registered there where a state runs a registry for interstate practice. The physician's location is irrelevant; yours is what counts. Pepti's serviceable footprint is defined by exactly this rule: a state is open only where a Pepti physician holds a license, and as of the current state-availability data that is all 50 states and Washington, D.C.

The same tracker notes that "most states consider using only an internet/online questionnaire to establish a patient-provider relationship (needed to write a prescription in most states) as inadequate," and that some states require an examination before a prescription, which some specifically allow by telehealth. This is why a serious provider does more than collect answers: the physician can put a request on hold to ask a question, request labs, or move to video. Pepti's published terms describe care as "asynchronous messaging, questionnaire-based assessment, and video where needed." Federal law adds a further layer for controlled substances prescribed online; it does not apply here, because the peptide therapies prescribed through Pepti are not controlled substances.

The free online assessment collects your goals, health history, current medications, allergies, sex, height and weight. Medications and allergies are mandatory: the intake will not submit without them, and "none" is an answer. Incomplete or inconsistent answers are a reason to decline. Payment is taken at checkout, before review, so the pharmacy can ship the moment a physician approves; anything not prescribed is refunded.

You provide a photo of a government-issued ID, matched to the name and date of birth on your intake. No prescription is written for an unverified identity.

A physician licensed in your state reads the intake; Pepti's stated window is review within 24 hours. The physician screens your history against the medication requested: for GLP-1s, personal or family history of medullary thyroid carcinoma or MEN-2, pancreatitis, and pregnancy or planned pregnancy; for every treatment, pregnancy and breastfeeding. Current medications are checked against the request. Where a medication requires labs, recent bloodwork has to be on file before the prescription is written; at-home blood testing exists for that step.

The physician approves, places the request on hold to ask you a question through your account, or declines. A declined medication is refunded in full; on a multi-medication order only the declined line is refunded. The reason is recorded in your chart and you can message the physician about it. The prescribing physician is an independent medical professional, not a Pepti employee, and the decision is the physician's alone.

An approved prescription goes to a state-licensed, FDA-registered 503A pharmacy, which compounds it to the physician's order; Pepti's quality page describes its pharmacies as PCAB-accredited, with independent batch testing before release. The vial or cartridge ships with a fixed directions sheet written in units.

The physician authorizes a set number of refills at approval, and each refill is reviewed before it goes to the pharmacy rather than sent automatically. A monthly fill is one vial, cartridge or bottle. Dose changes are requested from your account and approved or declined by the physician. Questions and side effects go through your account or the app at no extra cost. Cancelling stops future refills and charges immediately, with no contract and no fee.

This is true of every compounded medication, peptide or otherwise. The FDA's compounding Q&A states: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." A 503A pharmacy, the kind that fills Pepti prescriptions, is state-licensed and, in the FDA's words, "the drugs must be compounded based on the receipt of valid patient-specific prescriptions." A 503B outsourcing facility is a separate category for larger-scale compounding, subject to manufacturing-practice requirements and FDA inspection. Neither produces an FDA-approved drug. A provider that tells you a compounded peptide is FDA approved is either confused or lying.

Because most peptides have no USP monograph and are not components of approved drugs, they depend on the third door in section 503A: the FDA's list of bulk drug substances. While that list is being built, the FDA has sorted nominated substances into three interim categories. Category 1 holds substances nominated with sufficient supporting information and no identified safety concern, which may be used under the interim policy. Category 2 holds substances the FDA has identified as raising "significant safety risks," against which it "would consider taking action." Category 3 holds substances nominated with insufficient information to evaluate.

On April 15, 2026 the FDA announced the removal of twelve peptide bulk drug substances from Category 2, so that they no longer carry the "significant safety risks" designation, and scheduled Pharmacy Compounding Advisory Committee meetings for July 23–24, 2026 and before the end of February 2027 to consider whether they belong on the 503A bulks list. The July meeting took place: on July 23 the committee considered BPC-157, KPV, TB-500 and MOTS-c, and on July 24 emideltide (DSIP), Semax and epitalon. The FDA's meeting page is explicit about what a vote means: "Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." Final FDA determinations were still pending when this page was written. The current status of any single peptide is on its own reference page, for example what BPC-157 is.

Two products in the table above sit differently. Semaglutide is the active ingredient of FDA-approved manufactured drugs, so a compounded version enters section 503A through the "component of an approved drug" door and is subject to the rule against compounding copies of commercially available products. Tesamorelin is the active ingredient of EGRIFTA, approved on November 10, 2010 for a specific indication in HIV-infected adults, and a compounded tesamorelin prescription for another purpose is off-label prescribing of a compounded product. In neither case is the compounded vial itself FDA approved. The regulatory picture is a reason to want a physician, not to avoid one: it is the framework a licensed provider operates inside, and a research-chemical vendor operates outside all of it.

STEP 1 (New England Journal of Medicine, 2021) randomized adults with overweight or obesity to once-weekly semaglutide or placebo over 68 weeks; STEP 5 (Nature Medicine, 2022) followed a similar population for two years; SELECT (New England Journal of Medicine, 2023) was a cardiovascular-outcomes trial in adults with obesity and established cardiovascular disease but without diabetes. A physician prescribing semaglutide is prescribing inside a large human evidence base, which is also why the screening questions for it are so specific.

Tesamorelin was tested in randomized placebo-controlled trials in HIV-infected adults with abdominal fat accumulation (New England Journal of Medicine, 2007; JAMA, 2014) and in a smaller randomized trial in obese adults with reduced growth-hormone secretion (Journal of Clinical Endocrinology and Metabolism, 2012). Sermorelin was studied in randomized trials in older adults (Journal of Clinical Endocrinology and Metabolism, 1997; Archives of Neurology, 2012). Human data for both are real; the populations were specific, and prescribing outside them rests on mechanism plus clinical judgment.

The cell and animal work on GHK-Cu describes stimulation of collagen synthesis in cultured fibroblasts (FEBS Letters, 1988) and connective-tissue accumulation in rat wounds (Journal of Clinical Investigation, 1993). The human studies are topical: ulcers in patients with diabetes (Wound Repair and Regeneration, 1994) and laser-resurfaced skin (Archives of Facial Plastic Surgery, 2006). There are no randomized human trials of injectable GHK-Cu, which is the form KLOW contains.

There are no randomized controlled trials of BPC-157 in humans. The literature is animal and cell work: Achilles-tendon reattachment in rats (Journal of Orthopaedic Research, 2006), growth-hormone receptor upregulation in cultured tendon fibroblasts (Molecules, 2014), and a gastrointestinal literature reviewed in Current Pharmaceutical Design (2011, 2018). TB-500 is a fragment of thymosin beta-4; the parent protein has a randomized placebo-controlled dose study in healthy volunteers (Annals of the New York Academy of Sciences, 2010) and a phase 2 randomized trial as an eye drop in dry eye (Cornea, 2015), but TB-500 itself has no randomized human trials. KPV has murine inflammatory-bowel-disease data (Gastroenterology, 2008) and no randomized human trials. A physician who prescribes any of these is prescribing on mechanism and experience, and should say so.

PT-141 (bremelanotide) has a modern randomized evidence base in premenopausal women with hypoactive sexual desire disorder (Women's Health, 2016; Obstetrics and Gynecology, 2019) plus earlier controlled studies in men (International Journal of Impotence Research, 2004). DSIP's human trials are small double-blind studies in chronic insomniacs from the 1980s and early 1990s (Lancet, 1981; Neuropsychobiology, 1992). Both have human data; the size, age and population differ, and a physician weighs that.

If every peptide had a STEP 1 behind it, a checklist could prescribe. Because the evidence ranges from large outcomes trials to rat tendons, someone has to decide, for a specific person with a specific history, whether the case matches the request. That someone has to be licensed where you live, able to say no, and reachable afterwards. That is what "do you need a doctor" actually means.